AVEDRO, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
+0.61% | -.--% |
| 2019 | Avedro, Inc.(NasdaqGM:AVDR) dropped from S&P TMI Index | CI |
| 2019 | Avedro, Inc. Announces Board Changes | CI |
Presenter SpeechReza Zadno (Executives)My name is Reza Zadno. I'm President and CEO of Avedro,...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Avedro Inc is a United States-based company. The Company is an ophthalmic pharmaceutical and medical device company developing and commercializing a suite of products based on its corneal collagen cross-linking technology platform to address a wide variety of ophthalmic disorders and conditions, primarily associated with corneal weakness. Its primary components of the Avedro Cross-Linking Platform are pharmaceutical formulations of riboflavin (vitamin B2), a âsingle dose pharmaceutical,â sold primarily in conjunction with the Companyâs innovative devices for the delivery of metered doses of ultraviolet (UVA) light, a medical device.
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 403M | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- AVDR Stock
- News Avedro, Inc.
- Transcript : Avedro, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-14-2019 05
